Arcturus Therapeutics Holdings Inc. (ARCT) — Analyst outlook / Analyst consensus target is. Based on 21 analyst ratings, the consensus is bullish — 12 Buy, 5 Hold, 4 Sell.
The consensus price target is $22.50 (low: $20.00, high: $25.00), representing an upside of 159.2% from the current price $8.68.
Analysts estimate Earnings Per Share (EPS) of $-2.43 and revenue of $0.17B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3.00 vs est $-2.43 (missed -23.3%). 2025: actual $-2.40 vs est $-2.06 (missed -16.3%). Analyst accuracy: 84%.
ARCT Stock — 12-Month Price Forecast
$22.50
▲ +159.22% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for Arcturus Therapeutics Holdings Inc., the average price target is $22.50, with a high forecast of $25.00, and a low forecast of $20.00.
The average price target represents a +159.22% change from the last price of $8.68.
Highest Price Target
$25.00
Average Price Target
$22.50
Lowest Price Target
$20.00
ARCT Analyst Ratings
Buy
Based on 21 analysts giving stock ratings to Arcturus Therapeutics Holdings Inc. in the past 3 months
EPS Estimates — ARCT
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$3.00
vs Est –$2.43
▼ 18.9% off
2025
Actual –$2.40
vs Est –$2.06
▼ 14.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ARCT
71%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.138B
vs Est $0.169B
▼ 22.5% off
2025
Actual $0.067B
vs Est $0.091B
▼ 35.0% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
